South Africa's Biovac Institute is getting a big shot in the arm from Pfizer. The U.S. drugmaker has agreed to transfer to the public-private group the technology necessary for it to produce Pfizer's best-selling vaccine, Prevenar 13.
All eyes are on Allergan's friendly deal talks with Pfizer, which is anxious to scoop up an acquisition and complete a tax inversion. But with the Irish drugmaker's execs mum on the possible combo Wednesday, the conversation turned to new product launches, drug pricing, and Q3 financials that looked "pretty good."
Partners Merck KGaA and Pfizer are looking to prove their 5th-place immuno-oncology treatment can contend with the leaders in the field, launching a late-stage lung cancer study to establish the antibody's promise.
Pfizer knows adults generally don't think they're at risk for pneumococcal pneumonia. So to get them to listen up about pneumonia-blocker Prevnar 13, it linked the disease to those they do take seriously.
For the first time since 2013, Bristol-Myers Squibb reported a year-over-year quarterly ad spending increase. Advertising and product promotion costs rose 13% to $193 million, following two quarters of double-digit decreases this year--and a 14% overall decrease for all of 2014. The last time ad spending was up year over year was 2013's fourth quarter.
In South Africa, 40% of the national budget for vaccines is used to import Pfizer's Prevenar 13, according to Science and Technology Minister Naledi Pandor. To ease this burden, Pfizer and South Africa's Biovac Institute are entering a 5-year partnership to produce the vaccine domestically, Reuters reported.
Pfizer admits it's wooing Allergan for a merger worth more than $100 billion. But what it's not saying publicly is that GlaxoSmithKline has rejected its advances. That's the word from the Financial Times, whose sources say Pfizer had been flirting with a GSK buy, but the U.K.-based drugmaker wasn't impressed. Pfizer duly backed away.
The first subject in a Phase I study of Pfizer's subcutaneous sickle cell anemia candidate has been dosed, triggering $1 million milestone payment to Halozyme, developer of the enhanze drug delivery platform.
The deal of the year could be arranged by Thanksgiving, or so goes the story. Despite opposition from politicians, despite the tricky nature of pulling off a tax inversion that size, Pfizer and Allergan may well be engaged before the month is out, giving Pfizer its long-sought tax reduction and its answer to the who-will-you-buy question that's popped up on every earnings call since AstraZeneca's final rejection last year.
The FDA and European regulators, which have long had concerns about the quality of drugs being manufactured by Chinese companies, are now finding issues at some Chinese plants owned by Big Pharma. The FDA has cited a Pfizer plant in China, while U.K. regulators recently found shortcomings at a GlaxoSmithKline plant there.